JO3376B1 - خليط متحد مضاد للفيروسات المسببة للاورام - Google Patents

خليط متحد مضاد للفيروسات المسببة للاورام

Info

Publication number
JO3376B1
JO3376B1 JOP/2012/0207A JOP20120207A JO3376B1 JO 3376 B1 JO3376 B1 JO 3376B1 JO P20120207 A JOP20120207 A JO P20120207A JO 3376 B1 JO3376 B1 JO 3376B1
Authority
JO
Jordan
Prior art keywords
retroviral combination
retroviral
combination
darunavir
ritonavir
Prior art date
Application number
JOP/2012/0207A
Other languages
English (en)
Inventor
Lulla Amar
Malhotra Geena
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54289250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3376(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Application granted granted Critical
Publication of JO3376B1 publication Critical patent/JO3376B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/78—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling
    • B29C48/80—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling at the plasticising zone, e.g. by heating cylinders
    • B29C48/83—Heating or cooling the cylinders
    • B29C48/832—Heating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Mechanical Engineering (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

توجد هناك مركبات صيدلانية من ريتونافير ودارونافير كما توجد هناك طرق لانتاجه.
JOP/2012/0207A 2007-12-24 2012-07-29 خليط متحد مضاد للفيروسات المسببة للاورام JO3376B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2538MU2007 2007-12-24

Publications (1)

Publication Number Publication Date
JO3376B1 true JO3376B1 (ar) 2019-03-13

Family

ID=54289250

Family Applications (2)

Application Number Title Priority Date Filing Date
JO2008578A JO2814B1 (ar) 2007-12-24 2008-12-24 خليط متحد مضاد للفيروسات المسببة للأورام
JOP/2012/0207A JO3376B1 (ar) 2007-12-24 2012-07-29 خليط متحد مضاد للفيروسات المسببة للاورام

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JO2008578A JO2814B1 (ar) 2007-12-24 2008-12-24 خليط متحد مضاد للفيروسات المسببة للأورام

Country Status (20)

Country Link
US (1) US9339470B2 (ar)
EP (2) EP2505193B1 (ar)
JP (2) JP2011507940A (ar)
CN (2) CN103638032A (ar)
AP (2) AP2855A (ar)
AT (1) ATE555778T1 (ar)
AU (1) AU2008339633A1 (ar)
BR (1) BRPI0819534A2 (ar)
CA (1) CA2710605C (ar)
DK (1) DK2242482T3 (ar)
ES (2) ES2674730T3 (ar)
GT (1) GT200800303A (ar)
HK (1) HK1149905A1 (ar)
JO (2) JO2814B1 (ar)
MX (1) MX2010007083A (ar)
PA (1) PA8809601A1 (ar)
PE (2) PE20091530A1 (ar)
RU (2) RU2531089C2 (ar)
WO (1) WO2009081174A2 (ar)
ZA (1) ZA201004505B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8809601A1 (es) 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
ES2516916T3 (es) 2010-01-28 2014-10-31 Mapi Pharma Limited Procedimiento para la preparación de darunavir e intermedios de darunavir
WO2012088305A1 (en) * 2010-12-22 2012-06-28 The Feinstein Institute For Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors
ES2651212T3 (es) * 2011-07-07 2018-01-25 Janssen Sciences Ireland Uc Formulaciones combinadas de darunavir
AU2012280277B2 (en) * 2011-07-07 2017-02-09 Janssen Sciences Ireland Uc Darunavir formulations
US20150086628A1 (en) * 2012-05-03 2015-03-26 Cipla Limited Antiretroviral composition
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
EP3038607A2 (en) 2013-08-29 2016-07-06 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
WO2018029561A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
RU2760129C1 (ru) * 2020-12-04 2021-11-22 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального антиретровирусного терапевтического средства

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
AU641375B2 (en) 1988-12-20 1993-09-23 Clarity Technologies Incorporated Synthetic HIV-like peptides, their compositions and uses
WO1990007199A1 (en) 1988-12-20 1990-06-28 Mawzones Developments Limited Focussing device for a microwave antenna
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein
DK0727419T3 (da) 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
WO1999067254A2 (en) 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
TWI286476B (en) 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
RU2275361C3 (ru) 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1765337B1 (en) 2004-07-08 2008-08-27 Tibotec Pharmaceuticals Ltd. Combination of tenofovir, ritonavir and tmc114
JP2008520672A (ja) * 2004-11-16 2008-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
SI2051703T1 (sl) * 2005-12-14 2011-01-31 Cipla Ltd Farmacevtski sestavki, ki vsebujejo inhibitorje nukleotidne in nukleozidne reverzne transkriptaze (kot tenofovir in lamivudin) v različnih delih dozirne oblike
PA8809601A1 (es) 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral

Also Published As

Publication number Publication date
CN103638032A (zh) 2014-03-19
EP2505193B1 (en) 2018-05-02
PA8809601A1 (es) 2009-07-23
AP2010005325A0 (en) 2010-08-31
ES2385819T3 (es) 2012-08-01
EP2505193A1 (en) 2012-10-03
JP2015007071A (ja) 2015-01-15
DK2242482T3 (da) 2012-08-06
JP2011507940A (ja) 2011-03-10
RU2014111723A (ru) 2015-10-10
CA2710605A1 (en) 2009-07-02
PE20140926A1 (es) 2014-08-06
WO2009081174A3 (en) 2009-08-27
CN101925350B (zh) 2014-04-30
RU2531089C2 (ru) 2014-10-20
BRPI0819534A2 (pt) 2015-05-26
ATE555778T1 (de) 2012-05-15
CA2710605C (en) 2017-05-02
JO2814B1 (ar) 2014-09-15
WO2009081174A2 (en) 2009-07-02
RU2675831C2 (ru) 2018-12-25
US20110008429A1 (en) 2011-01-13
AU2008339633A1 (en) 2009-07-02
RU2010131006A (ru) 2012-02-10
ES2674730T3 (es) 2018-07-03
AP2013007064A0 (en) 2013-08-31
US9339470B2 (en) 2016-05-17
ZA201004505B (en) 2013-05-29
MX2010007083A (es) 2010-10-20
EP2242482A2 (en) 2010-10-27
GT200800303A (es) 2009-09-18
EP2242482B1 (en) 2012-05-02
AP2855A (en) 2014-02-28
CN101925350A (zh) 2010-12-22
PE20091530A1 (es) 2009-09-25
HK1149905A1 (en) 2011-10-21

Similar Documents

Publication Publication Date Title
JO3376B1 (ar) خليط متحد مضاد للفيروسات المسببة للاورام
IL262205A (en) Protein formulations and methods for their preparation
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
HK1210420A1 (en) Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
IL195491A (en) Pharmaceutical preparations containing tmc278 and processes for their preparation
EP2136634A4 (en) MIMETIC GLUCOCORTICOID SUBSTANCES, PREPARATION METHODS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP2152304A4 (en) THERAPEUTIC COMPOSITIONS IN NANOEMULSION FORM AND METHOD OF APPLICATION THEREFOR
ZA200902803B (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP2490679B8 (en) Methods of making and using compositions comprising flavonoids
EP2429948A4 (en) Aerogel compositions and methods of making and using them
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
HK1175947A1 (en) Pharmaceutical compositions and methods of making same
ZA201008379B (en) Glucocorticoid mimetics,methods of making them,pharmaceutical compositions,and uses thereof
EP2254555A4 (en) APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
EP2506835A4 (en) COMPRESSIBLE COATED PHARMACEUTICAL COMPOSITION, TABLETS AND MANUFACTURING METHOD THEREFOR
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
EP2491116A4 (en) CELL-BASED ANTI-RISK COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
EP2254420A4 (en) CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
HK1177695A1 (en) Pharmaceutical composition comprising vitamin d analogue and cosolvent- surfactant mixture d-
EP2051721A4 (en) PREPARATION AND PHARMACEUTICAL USE OF COMPOSITION FROM THE EXTRACT OF EUTERPE OLERACEA (ACAI)
MX2009012643A (es) Particulas de alumina y metodos para fabricar las mismas.
MX2010004734A (es) Nueva combinacion anti-retrovirica.
IL219018A (en) Radzolid Pharmaceuticals and Uses
MX2013005699A (es) Composiciones de interferon-beta estables conservadas.